Ronald J. Daniels - 28 Dec 2021 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Role
Director
Signature
Yi Ching Yau, Attorney-in-Fact
Issuer symbol
BBIO
Transactions as of
28 Dec 2021
Net transactions value
+$148,343
Form type
4
Filing time
30 Dec 2021, 19:17:00 UTC
Previous filing
22 Jun 2021
Next filing
24 Jun 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BBIO Common Stock Purchase $149,514 +11,745 $12.73 11,745 28 Dec 2021 Direct F1, F2
transaction BBIO Common Stock Sale $150,336 -11,745 -100% $12.80 0 28 Dec 2021 Direct F1, F3
transaction BBIO Common Stock Purchase $149,165 +10,402 $14.34 10,402 30 Dec 2021 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person realized short-swing profits under Section 16(b) of the Securities Exchange Act of 1934, as amended, as a result of the purchase and sale of the Issuer's common stock on December 28, 2021 reported herein. The Reporting Person has agreed to voluntarily disgorge to the Issuer all short-swing profits realized by the Reporting Person from such transactions.
F2 Represents the weighted average sale price of the shares sold from $12.7275 to $12.73 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported in footnotes 2 and 3.
F3 Represents the weighted average sale price of the shares sold from $12.79 to $12.82 per share.